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SUMMARY
Objective: To prospectively evaluate the etiology of new-onset infantile spasms and
evaluate the yield of genetic and metabolic investigations in those without obvious
cause after initial clinical evaluation andmagnetic resonance imaging (MRI).
Methods: Twenty-one U.S. pediatric epilepsy centers prospectively enrolled infants
with newly diagnosed West syndrome in a central database. Etiology and investiga-
tions performedwithin 3 months of diagnosis were documented.
Results: From June 2012 to June 2014, a total of 251 infants were enrolled (53% male).
A cause was identified in 161 (64.4%) of 250 cases (genetic,14.4%; genetic-structural,
10.0%; structural-congenital, 10.8%; structural-acquired, 22.4%; metabolic, 4.8%; and
infectious, 2.0%). An obvious cause was found after initial clinical assessment (history
and physical examination) and/or MRI in 138 of 161, whereas further genetic andmeta-
bolic studies were revealing in another 23 cases. Of 112 subjects without an obvious
cause after initial evaluation and MRI, 81 (72.3%) had undergone genetic testing, which
showed a causal abnormality in 23.5% and a variant of unknown significance in 14.8%.
Althoughmetabolic studies were done in themajority (serum, 79.5%; urine, 69.6%; and
cerebrospinal fluid [CSF], 38.4%), these revealed an etiology in only five cases (4.5%).
No correlation was found between type of health insurance (public vs. private) and
either genetic ormetabolic testing.
Significance: Clinical evaluation and MRI provide a specific diagnosis in 55% of children
presenting with West syndrome. We propose that a cost-effective workup for those
without obvious cause after initial clinical evaluation and MRI includes an array com-
parative genomic hybridization (aCGH) followed by an epilepsy gene panel if the
microarray is not definitive, serum lactate, serum amino acids, and urine organic
acids.
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West syndrome is the most common epileptic encepha-
lopathy in the first 2 years of life.1–3 It consists of a triad of
(1) epileptic spasms, (2) hypsarrhythmia on interictal elec-
troencephalography (EEG), and (3) developmental arrest or
psychomotor delay.
Traditionally, infantile spasm etiology was classified as
symptomatic or cryptogenic.4 Symptomatic spasms had a
clear underlying cause and/or significant developmental
delay preceding seizure onset, whereas the term cryptogenic
was used if no underlying cause was found and normal
development preceded the spasms. The term idiopathic was
used to describe patients with normal development at onset,
normal examination and neuroimaging, and a hypsarrhyth-
mia pattern without focal abnormalities.5 However, the
most recent proposal by the Commission on Classification
and Terminology of the International League Against Epi-
lepsy (ILAE) proposes replacing these terms with specific
etiologic categories including genetic, structural/metabolic,
and unknown.6
With modern neuroimaging and advanced genetic test-
ing, the proportion of children with defined causes for their
spasms is increasing. In the United Kingdom Infantile
Spasms Study (UKISS), 61% had a proven etiology, 33%
had no identified etiology, and 6%were incompletely inves-
tigated.7 Details of specific metabolic and genetic testing
were not reported for children without an obvious etiology
at presentation.
We used the National Infantile Spasms Consortium
(NISC) database to determine the etiologies for a large, con-
temporary, prospective cohort of children with newly diag-
nosed infantile spasms. We identified the proportion of
patients with an obvious cause after initial clinical evalua-
tion and magnetic resonance imaging (MRI). For those
patients without obvious cause, we evaluated the yield of
genetic and metabolic investigations carried out in the first
3 months after diagnosis.
Methods
NISC is part of the Pediatric Epilepsy Research Consor-
tium (PERC), a network of 38 U.S. pediatric epilepsy aca-
demic centers. For this prospective, observational study, 21
centers enrolled newly diagnosed children with infantile
spasms, aged 2 to 24 months, between June 1, 2012 and June
1, 2014. Included children had a history consistent with epi-
leptic spasms and EEG showing hypsarrhythmia or modi-
fied hypsarrhythmia. Children were also included if the
EEG did not meet criteria for hypsarrhythmia, but had back-
ground slowing, multifocal spikes, and electroclinical
spasms. Children with early infantile epileptic encephalopa-
thy were excluded. Choice of diagnostic investigations was
determined by the treating neurologist.
Individual centers began patient entry at the time of local
institutional review board (IRB) approval (June 2012
through December 2013). Each patient’s parent or guardian
provided written informed consent. Data were entered at the
time of recruitment and updated 3 months after initial diag-
nosis. Thus, this study evaluates defined etiologies and
investigations performed during the first 3 months after
diagnosis. Data collected included underlying etiology; sig-
nificant prenatal, perinatal, and postnatal history; and
results of neuroimaging, genetic, and metabolic studies per-
formed prior to or during the first 3 months after diagnosis.
Because all children were assessed by a pediatric neurolo-
gist, we assumed each had undergone a careful neurologic
and general examination, including skin examination with a
Wood’s lamp and funduscopy, although did not record spe-
cific findings of those examinations.
Determination of etiology
Etiology was coded by two independent reviewers into
etiology class and most likely specific etiology(ies) based
on the etiologies entered by site investigators, along with
significant pre-, peri-, and postnatal complications; prior
provoked seizures; and results of investigations. When the
reviewers’ coding differed, a third reviewer was consulted
to reach final consensus.
Etiology class was divided into eight subgroups
(Table 1), along with specific etiology, based on results of
all recorded investigations. Infants with spasms of unknown
cause were subdivided into those with normal development
versus those with definite or suspected delay.
If there was a disparity between the diagnosis entered by
the site investigator and the result of a specific investigation,
the final diagnosis coded reflected the test result. If the
Table 1. Etiologic categories
Genetic: Genetic disorders that were felt to be likely causes of
epilepsy, but were not associated with structural brain changes on
imaging (i.e., Down syndrome)
Genetic-structural: Genetic disorders that result in structural brain
changes, which result in epilepsy (i.e., tuberous sclerosis, DCX
mutation)
Structural-congenital: Malformative changes in the brain without a
documented genetic etiology (i.e., focal cortical dysplasia,
schizencephaly)
Structural-acquired: Structural brain change resulting from some type
of injury or tumor. Included here are both perinatal (i.e.,
periventricular leukomalacia, intraventricular hemorrhage, and
neonatal hypoxic-ischemic injury) or postnatal (i.e., ischemia,
trauma, and tumor) etiologies
Metabolic: Metabolic disorder causing brain dysfunction leading to
seizures. These conditions are nearly all inborn errors of
metabolism, and many have a genetic inheritance. Disorders due to
an inborn error of metabolism with resultant structural brain
changes were coded as metabolic (i.e., POLG1 orWalker-Warburg
syndrome)
Immune: Documented immunologic disorder that results in
perturbation of brain function with seizures
Infectious: Documented or highly suspected brain infection resulting
in epilepsy (i.e., TORCH infection, HIV)
Unknown: No known etiology found for seizures
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history or investigations suggested but did not confirm a dif-
ferent etiology, the site investigator was contacted for clari-
fication.
Investigations within 3 months of diagnosis of infantile
spasms
The specific genetic, metabolic, and immune studies
were coded by two independent reviewers, and where dis-
agreement occurred, a third reviewer adjudicated the result.
Genetic testing
The type of test (karyotype, array comparative genomic
hybridization (aCGH), targeted single nucleotide polymor-
phism array, specific gene testing, epilepsy panel, whole
exome/genome sequencing, mitochondrial single nucleo-
tide polymorphism array, and mitochondrial panel) and
results were recorded. Results were classified as normal,
clearly abnormal, or variants of uncertain significance
(VUS). Clear abnormalities were genetic mutations that
were indicated to be pathogenic based on the lab report and/
or review of the medical literature.
Metabolic testing
Results of testing for glucose, calcium and other electro-
lytes, and renal and liver function, were not recorded, as
these are performed routinely. Instead, specific metabolic
studies requested from blood/serum, urine, and cerebrospi-
nal fluid (CSF), and their results were noted (normal/non-
significant changes vs. abnormal).
Immune testing
Immune studies, including CSF oligoclonal bands,
serum, and CSF paraneoplastic panels were recorded.
Data analysis
The percentage of subjects in each etiologic group and
those undergoing specific investigations are presented.
We defined two groups, based on whether an obvious
cause for spasms was found after the initial clinical evalua-
tion and brain MRI. Children who had (1) a diagnostic
abnormality on MRI, (2) dysmorphic features highly sug-
gestive of a particular diagnosis (i.e., Down syndrome), or
(3) a previously diagnosed condition that is strongly associ-
ated with infantile spasms (i.e., tuberous sclerosis, perinatal
brain injury, and so on) were defined as having an obvious
cause at diagnosis. Those lacking these three criteria were
defined as having no obvious cause at diagnosis.
Cognitive and motor development were defined as normal,
clearly abnormal, or suspect based on the medical record.
The relationship between (1) an obvious cause at diagnosis
and (2) abnormal development at initial presentation and the
ordering of genetic or metabolic testing was assessed.
We stratified our cohort to assess the effect of insurance
type on ordering of investigations in infants without obvious
cause at diagnosis. Insurance types included public
(publicly funded health care, e.g., Medicaid or other state
insurance), private (e.g., health care insurance through a pri-
vate health maintenance organization or preferred provider
organization), and other (e.g., self-pay, uninsured, or other).
Potential predictors of ordering particular investigations
were compared between groups, using chi-square and
t-tests.
Results
Between June 2012 and June 2014, a total of 251 children
with newly diagnosed infantile spasms were prospectively
recruited from 21 U.S. pediatric epilepsy centers. Baseline
data were entered for all subjects; however, 3-month data
were missing in 20 (8.0%) of 251. Demographics are shown
in Table 2. Mean age at onset of spasms was 7.1 months
(standard deviation [SD] 3.6, range 0.1–22.7), and 134
(53.4%) were male.
Of these 251 children, 249 (99.2%) had West syndrome
and 2 (0.8%) had been diagnosed previously with early
myoclonic encephalopathy, which evolved to West syn-
drome. Forty-five children had prior provoked seizures,
including 23 (9.2%) with acute symptomatic neonatal sei-
zures, 3 (1.2%) with febrile seizures, and 19 (7.6%) with
other provoked seizures.
Table 2. Demographic details of cohort with spasms
(N = 251)
Male sex 134 (53.4%)
Ethnicity
Hispanic 29 (11.4%)
Non-Hispanic 183 (71.8%)
Unknown 43 (16.9%)
Race
Caucasian 159 (63.3%)
African American 32 (12.7%)
Asian 8 (3.2%)
Native Hawaiian or Pacific Islander 2 (0.8%)
First Nations 1 (0.4%)
Other 24 (9.6%)
Unknown 25 (10.0%)
Mean age at spasms onset
(SD, range) in months
7.1 (SD3.6, range 0.1–22.7)
Gestational age
<28 weeks 10 (4.0%)
28 to <32 weeks 11 (4.4%)
32 to <36 weeks 26 (10.4%)
≥36 weeks 199 (79.3%)
Unknown 5 (2.0%)
Prenatal or perinatal
complications (3 unknown)
113/248 (45.6%)
Insurance type
Public 93 (37.1%)
Private 112 (44.6%)
Self-Pay/Uninsured 1 (0.4%)
Other 3 (1.2%)
Unknown 42 (16.7%)
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Etiology of infantile spasms
Etiology data were missing for one subject (Fig. 1,
Table S1). Figure 1 lists the causes divided into etiologic
categories and Table S1 lists details of specific causes,
including type of structural, genetic, or metabolic disorder
found. An obvious cause at diagnosis was present in 138
(55.2%) of 250 cases. Following investigations performed
within 3 months of initial presentation, an underlying etiol-
ogy was found in another 23 cases. Thus, 64.4% of patients
had a known etiology for spasms: genetic alone, 14.4%;
genetic-structural, 10.0%; structural, 33.2% (congenital,
10.8%; acquired, 22.4%); metabolic, 4.8%; infection, 2.0%;
and unknown, 35.6%.
Down syndrome was the most common genetic cause
(N = 15), accounting for 42% of purely genetic etiologies,
and tuberous sclerosis accounted for nearly half of genetic-
structural etiologies (N = 12). Of the structural-acquired
causes, 33 (58.9%) of 56 were a result of perinatal brain
injury.
Causes were further defined as pre-, peri-, and postnatal.
Prenatal causes, including genetic, genetic-structural, struc-
tural-congenital etiologies, and toxoplasmosis, other (syphi-
lus, varicella-zoster, parvovirus B19), rubella,
cytomegalovirus and herpes infection (TORCH) infections
accounted for 93 (57.8%) of those with known etiologies.
Perinatal causes, including perinatal structural-acquired
causes, were causal in 39 cases (24.2%). Postnatal causes,
including tumor, trauma, metabolic disease, postnatal infec-
tion, ischemia, or stroke accounted for 29 cases (18%).
Investigations for spasms
Neuroimaging
Neuroimaging study details were available for 249 chil-
dren. Brain MRI was obtained in 218 (87.6%), either prior
to spasm onset, due to preexisting neurologic abnormalities,
or in the 3 months after diagnosis (171 with dedicated sei-
zure protocol and 47 using routine, nonseizure protocols).
MRI evaluations were ordered but not completed in another
six subjects. Of the 25 without MRI, 9 had confirmed
genetic causes, 10 had structural causes confirmed on prior
computed tomography (CT) or cranial ultrasound, and 6 had
unknown cause.
Of the 171 cases who had MRI with dedicated seizure
protocols, 70 (40.9%) showed causal abnormalities (35 mal-
formations of cortical development, 27 acquired structural
brain abnormalities, 5 changes suggestive of an inborn error
of metabolism, and 3 TORCH infection) and 9 (5.3%)
showed minor, noncausal changes (2 remote small cerebellar
hemorrhage, 2 delayed myelination, 1 mild white matter vol-
ume loss in child later found to have a genetic etiology, 1
mild atrophy, 1 old, small, bifrontal subdural hemorrhage, 1
mega cisterna magna, and 1 developmental cyst). Of the 47
cases with MRI without dedicated seizure protocol, 39
(83.0%) showed causal abnormalities (15 malformations of
cortical development, 1 with protein-O-mannosyltransferase
1 (POMT1) Walker-Warburg, 21 acquired structural brain
abnormalities, and 2 TORCH infection) and none were
reported to show nonspecific changes.
Genetic investigations
Genetic studies were performed on 141 children (56.2%),
of whom 32 (12.7%) had studies prior to onset of spasms
(Fig. 2A,B). Compared to children with an obvious cause at
diagnosis, those without an obvious cause at diagnosis were
more likely to undergo aCGH (p < 0.001), epilepsy gene
panel (p = 0.001), and karyotype (p = 0.019).
Among those with an obvious etiology at diagnosis, all
causal mutations detected were associated with their obvi-
ous etiology, including six children with malformations of
cortical development, five with tuberous sclerosis, one with
Leigh disease, and two with dysmorphisms in keeping with
a specific genetic syndrome (Pretzel syndrome and Schin-
zel-Giedion syndrome).
Karyotype. Karyotype was done in 32 children (12.7%),
with abnormalities found in 17 (85%) of 20 cases tested
prior to spasm onset (15 had Down syndrome), versus zero
of 12 after onset.
Array comparative genomic hybridization array
(aCGH). aCGH was performed in 87 children (34.7%). No
diagnostic abnormalities were seen in cases tested prior to
spasm onset, but definite abnormalities were reported in 12
(15%) and VUS in 9 (11%) tested after spasm onset.
Targeted chromosomal single-nucleotide polymorphism
(SNP). Targeted chromosomal single-nucleotide polymor-
phism (SNP) analysis was performed in four cases (1.6%)
and abnormalities were found in two (50%), confirming
Williams syndrome in one and lissencephaly 1 (LIS1) in the
other.
Targeted single gene testing. Targeted single gene testing
was performed in 24 cases (9.6%). Abnormalities were seen
Figure 1.
Etiological Class at diagnosis, and after 3 months of follow-up.
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in five cases (83.3%) tested prior to spasm onset, confirm-
ing mutations in doublecortin (DCX) (N = 1), kirsten rat
sarcoma viral oncogene (KRAS) with Noonan syndrome
(N = 1), POMT1 with Walker-Warburg (N = 1), neurofi-
bromatosis type 1 (NF1) (N = 1), and polyhydramnios,
megalencephaly and symptomatic epilepsy (PMSE) with
Pretzel syndrome (N = 1). Six (33.3%) of those tested
after spasm onset showed confirmatory mutations: tuber-
ous sclerosis (TSC) 1 or 2 (N = 3), glycine decarboxylase
(GLDC) in a child with nonketotic hyperglycinemia
(N = 1), PMSE in Pretzel syndrome (N = 1), and set-
binding protein 1 (SETBP1) in Schinzel-Giedion syn-
drome (N = 1). Single gene testing also showed two
VUS.
Epilepsy gene panel. Epilepsy gene panels were obtained in
34 cases (13.5%), showing diagnostic abnormalities in 11
(32.4%): cyclin-dependent kinase-like 5 (CDKL5) (N = 3),
voltage gated potassium channel 3 (KCNQ3) (N = 2), TSC2
(N = 2), one each with syntactin binding protein (STXBP1),
KAT8 regulatory NSL complex subunit 1 (KANSL1), poly-
merase gamma 1 (POLG1), and sodium channel 1A
(SCN1A), and VUS in 3.
Whole exome/whole genome sequencing. Four children
(1.6%) underwent either whole exome or whole genome
sequencing, all with normal results.
Targeted mitochondrial SNP. Four children (1.6%) under-
went targeted mitochondrial SNP. The single study done
prior to spasm onset confirmed a diagnosis of Leigh disease,
whereas all three studies done after spasm onset were normal.
Mitochondrial gene panel. Nine children (3.6%) underwent
a mitochondrial gene panel. Results were abnormal and
diagnostic in three cases (33.3%; two pyruvate dehydroge-
nase mutation, one ATP6mutation). One VUSwas detected.
Overall yield of genetic testing in children without an
obvious cause at diagnosis
Of the 112 children without obvious cause at diagnosis,
81 (72.3%) had undergone genetic testing, which showed a
causal abnormality in 19 (23.5%), and a VUS in another 12
(14.8%) (Fig. 2C). The diagnostic yield was zero (0%) of
10 for a karyotype, 7 (11.3%) of 62 with an aCGH, one
(33.3%) of 3 for targeted chromosomal SNP analysis, one
(11.1%) of 9 for targeted single gene analysis, 8 (30.8%) of
26 for an epilepsy gene panel, zero (0%) of 3 for whole
exome/genome sequencing, zero (0%) of 2 for a mitochr-
ondrial SNP analysis, and 2 (28.6%) of 7 for a mitochondrial
gene panel.
Causal abnormalities tended to be more likely, with
increased severity of delay, being detected in 2 (8.3%) of 24
with normal development, 4 (23.5%) of 17 with suspect
development, and 13 (32.5%) of 40 with clearly abnormal
development (p = 0.09).
We found no significant difference between type of
health insurance (public vs. private) and number of children
undergoing any type of genetic testing, including karyotype
(p = 0.77), aCGH (p = 0.14), targeted single gene analysis
(p = 0.41), and epilepsy gene panel (p = 0.51).
Among children still classified with unknown etiology
3 months after the diagnosis of spasms, 46 (51.7%) of 89
underwent aCGH, 17 (19.1%) of 89 an epilepsy gene panel,
4 (4.5%) of 89 mitochondrial genetic testing, and 3 (3.4%)
of 89 whole exome/genome sequencing.
Specialized metabolic investigations
Details on metabolic investigations ordered were
reported in all children, with the specific metabolic studies
A
B
C
Figure 2.
Yield of genetic testing. (A) Prior to diagnosis of spasms. (B) Entire
cohort; within 3 months after diagnosis of spasms. (C) Children
without obvious cause at diagnosis.
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ordered listed in Table S2 (Fig. 3). Of the 12 children with
a documented metabolic cause for spasms, 3 were diag-
nosed prior to spasm onset (one POLG1, one POMT1, and
one congenital hyperinsulinism and hypothyroidism). Four
exhibited MRI findings highly suggestive of metabolic dis-
ease at the time of presentation, with spasms, all confirmed
with further studies (two Leigh syndrome, one lactic acido-
sis, and one nonketotic hyperglycinemia).
Blood/serum studies. One hundred thirty-four children
(53.4%) underwent blood/serum metabolic testing, and of
these, a median of 4 (interquartile range 2–5 ) studies were
performed. Investigations were normal in 104 (77.6%) of
134, showed nonspecific findings in 23 (17.1%) of 134, and
were clearly abnormal in 7 (5.2%) of 134. Of the abnormal
studies, six showed markedly elevated lactate (one POLG1,
one complex 1 deficiency, one Leigh syndrome, and three
lactic acidosis), one elevated lactate and pyruvate and an
abnormal lactate/pyruvate ratio (lactic acidosis), and five
abnormal amino acids (one methylmalonic aciduria, two
lactic acidosis, one Leigh syndrome, and one nonketotic
hyperglycinemia). One child had an elevated insulin level
and low thyroid function, in keeping with congenital hyper-
insulinism and hypothyroidism.
Urine studies. One hundred four children (41.4%) under-
went urine metabolic testing, and of these, a median of 1 (in-
terquartile range 1–2) studies were performed. Results were
normal in 88 (84.6%) of 104, showed nonspecific findings
in 13 (12.5%) of 104, and were abnormal in 3 (2.9%) of 104,
one of whom had increased methylmalonic acid on urine
amino acids, and one with Leigh syndrome and another with
lactic acidosis, both of whom had marked abnormalities on
urine organic acids.
CSF studies. Fifty-five children (21.9%) underwent CSF
metabolic testing, with a mean of 4 (interquartile range 1–5)
studies performed. Results were normal in 43 (78.2%) of
55, showed nonspecific findings in 10 (18.2%) of 55, and
were abnormal in 2 cases (3.6%) (one elevated glycine due
to nonketotic hyperglycinemia, one elevated lactate with
POLG1).
Overall yield of metabolic testing in children without an
obvious cause at diagnosis
Children without an obvious cause at diagnosis were
more likely than those with a known cause to undergo
blood/serum (89/112 vs. 44/138, p < 0.001), urine (78/112
vs. 28/138, p < 0.001), and CSF metabolic testing (43/112
vs. 12/138, p < 0.001) (Fig. 3B). Of this group (N = 112),
metabolic studies revealed an etiology in only five cases
(one complex 1 deficiency, one pyruvate dehydrogenase
deficiency, two lactic acidosis, and one methylmalonic
aciduria), and serum lactate, pyruvate, amino acids, and
urine organic acids were the only metabolic studies showing
abnormalities. CSF testing did not reveal a metabolic etiol-
ogy in any of the patients undergoing such testing after
spasm presentation.
Developmental delay at presentation was not predictive
of higher likelihood of undergoing metabolic testing or of
greater yield of testing. There was no correlate between
insurance type (private vs. public) and undergoing further
blood/serum (p = 0.90), urine (p = 0.24), or CSF
(p = 0.28) metabolic testing, or in the number of metabolic
studies performed on blood/serum (p = 0.86), urine
(p = 0.83), or CSF (p = 0.35).
Of children still classified as unknown etiology after
3 months, metabolic studies were done in the majority
(blood/serum in 83.1%, urine in 70.8%, and CSF in 42.7%).
Immunologic investigations
Five children underwent immunologic studies (oligoclo-
nal banding-4, paraneoplastic panel-1, and anti-N-methyl-
D-aspartate [NMDA] receptor antibody testing-1) and all
were normal.
Discussion
In this prospective registry of newly diagnosed infantile
spasms, just over half (55.2%) had an obvious etiology iden-
A
B
Figure 3.
Yield of metabolic testing. (A) Entire cohort; testing done prior to
spasm onset or within first 3 months after diagnosis. (B) Children
without obvious cause at diagnosis.
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tified after initial clinical assessment and brain MRI. Many
of these children exhibited preexisting neurologic problems
and had undergone testing prior to spasm onset. The propor-
tion of children with an obvious etiology is lower in our
sample than suggested by a recent consensus report, which
states that after a thorough clinical history, examination,
EEG, and MRI, an etiologic diagnosis is possible in 70% of
children with infantile spasms, and of the remaining 30%
who undergo further metabolic or genetic investigations, a
defined cause is found in less than half.1 Among children in
our study without an obvious cause at the time of diagnosis
of spasms, just 21% yielded a definitive etiology established
within 3 months. Our results are similar to the those of the
UKISS, in which 61% of children with spasms had a proven
etiology when followed up to 14 months of age.7 However,
6% of cases in the UKISS were not adequately investigated
for an underlying cause, the majority of whom had not
undergone brain imaging.
Similar to the UKISS results, we found that prenatal
causes were most common, accounting for 57.8% of known
etiologies in our cohort and 49.6% in the United Kingdom
cohort.7 Of prenatal causes, we identified genetic etiologies
in approximately two thirds, with or without cerebral mal-
formations, which highlights the important, causal role of
genetics in this cohort of children. Parallel to the UKISS
cohort, we found that perinatal etiologies were causal in
approximately one fourth of known causes, with the most
common etiologies being hypoxic-ischemic encephalopathy
and brain injury of the preterm infant. This underscores the
importance of optimal prenatal and perinatal care in epi-
lepsy prevention. Postnatal causes accounted for 18.0% of
known causes in our group, compared to only 6.3% in the
UKISS cohort.
Of those patients who underwent imaging studies, brain
MRI demonstrated causal abnormalities in half of infants
with new-onset spasms, and thus is an appropriate and
necessary first-line investigation in cases without a
defined etiology. Our data show that MRI detected 86.2%
(119/138) of the known causes at initial presentation, and
73.2% (119/161) of causes at 3 months of follow-up. Of
112 cases without an obvious cause at presentation, in our
study 105 (94%) had either undergone MRI or had an
MRI pending. Of the remaining seven children, etiology
remained unknown in six after 3 months; their workup
was considered incomplete as they lacked an adequate
neuroimaging study. The recent guidelines from the ILAE
Subcommittee for Pediatric Neuroimaging recommend
special sequences including sagittal, axial, and coronal
T2-weighted sequences in addition to a three-dimensional
dataset in children younger than age 2 years, as immature
myelination limits the ability to identify cortical malfor-
mations.8 Furthermore, if the initial MRI is normal, and
seizures persist, an MRI may be repeated at 6-month
intervals to detect cortical dysplasia, and certainly after
age 24–30 months when myelination is more mature.
What is the yield of investigations in children without an
obvious cause after initial clinical evaluation andMRI?
Genetic and metabolic testing was performed in the
majority of our cases without obvious cause at diagnosis. Of
the 72% of cases undergoing genetic testing, a specific
genetic diagnosis was reached in 24% and VUS were
reported in another 15%. The highest yield genetic study
was the epilepsy gene panel, which resulted in an etiologic
diagnosis in 31%, but was done in <25% of cases. aCGHs
were performed in 55% and revealed a causative etiology in
11%. More than one half of those mutations affected the
15q region, which has been previously recognized as an
important locus for many types of epilepsy and intellectual
disability.9,10 Although the yield of detecting an etiologic
diagnosis was just over 25% with mitochondrial gene pan-
els, these were performed in only a small number of chil-
dren, most of whom had other metabolic findings
suggestive of a mitochondrial disorder.
Our results suggest that genetic testing, particularly with
an aCGH and epilepsy gene panel are high yield—the com-
bination of these two tests provided a definitive diagnosis in
>40% of children presenting with new-onset spasms without
an obvious cause after initial clinical evaluation andMRI.
Other studies have emphasized the importance of careful
genetic evaluation in children with epileptic encephalopa-
thies.11–13 Paciorkowski et al.14 recently classified impor-
tant genes predisposing to infantile spasms, based on their
pathogenic mechanisms. Increasingly, outside of rare and
very specific clinical scenarios, epilepsy gene panels are
preferred over targeted gene testing, as they allow for test-
ing of a large number of genes at a cost of approximately
$5,000 USD, which is comparable to targeted testing of
only one to two individual genes (approximately $1,000–
3,000 USD per gene). Whole exome sequencing has been
shown to be high yield in unexplained infantile spasms15;
however, as only a minority of children in our cohort under-
went this study, we cannot comment on the yield of such
testing.
Despite the high yield of genetic testing in this setting,
our findings suggest that genetic investigations remain un-
derutilized in many patients. Somewhat surprisingly, we did
not find any difference in ordering of genetic tests based on
insurance type. This could be related to state-to-state differ-
ences in public insurance coverage for genetic testing; dif-
fering relationships between genetics and neurology
clinicians; the practice of sending costly testing during inpa-
tient admissions to avoid direct billing of families; or other
undetermined factors. Still, we speculate that difficulties
with insurance approval, which occur both with public and
private insurance, contribute substantially to this underutili-
zation. Discovering a genetic etiology is important for sev-
eral reasons. First, it provides a cause and prevents ongoing,
invasive and expensive diagnostic investigations. Second, it
may increase understanding of the pathogenesis and poten-
tially provide avenues for future, more targeted and better
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therapies, or even preventive strategies. Third, it may have
an effect on genetic counseling for future pregnancies.
Metabolic studies were performed in the majority of
children without an obvious cause, but the yield of such
testing was relatively low, with definitive diagnoses
reached in only 4.5%. Diagnostic abnormalities were found
only on serum lactate, pyruvate, amino acids, and urine
organic acid testing. All four children with findings sug-
gestive of neurometabolic disorders on initial MRI, but
who had not been previously diagnosed with a metabolic
condition, were found to have metabolic diagnoses on fur-
ther testing, underscoring the importance of targeted evalu-
ation in this subgroup. Although a recent study from China
reported a higher rate (22%) of inborn errors of metabolism
in infants with newly diagnosed spasms,16 neuroimaging
was abnormal in 62% of reported cases, and their cohort
included disorders which are diagnosed by routine new-
born screening in the United States, such as phenylketon-
uria and biotin deficiency.
Our study has some important strengths and limitations.
Our sample is large, contemporary, and performed in a
wealthy country in which most children have excellent
access to investigations. We had representation of patients
in multiple regions of the United States; however, the pro-
file of etiologies and testing might not be generalizable to
children cared for in other geographic locations outside the
United States. Our study did not have a population-based
design, and our sample was derived from children treated at
tertiary pediatric epilepsy centers, which may enrich for
some of the rarer causes of infantile spasms. Still, our
patient population reflected many of the most commonly
reported etiologies.
Genetic and metabolic testing protocols were determined
by the individual treating clinicians without a mandated
testing protocol. This allowed for evaluation of a wide vari-
ety of tests. However, there was substantial practice vari-
ability between our 21 centers regarding genetic and
metabolic testing. We are unable to account for the attitudes
of the individual clinical teams toward, and/or rationale for,
ordering specific tests, and we were not able to discuss fami-
lies’ preferences for specific testing strategies.
Finally, only data from the first 3-month follow-up were
analyzed. Because 3-month follow-up data were missing in
8% of cases, and genetic testing results often take 3 months
or longer, it is probable that we are missing genetic etiolo-
gies that would be apparent with longer and more complete
follow-up. Repeat, dedicated MRIs using seizure protocol
may also identify subtle cortical dysplasias as myelination
progresses in the developing brain.
Based on the results of our contemporary, large, multi-
center U.S. study, we propose that a cost-effective workup
in children presenting with newly diagnosed West syn-
drome, without an obvious cause after clinical history, phys-
ical examination, and MRI should include aCGH, followed
by an epilepsy gene panel if the microarray is not definitive;
serum lactate; serum amino acids; and urine organic acids.
If these studies are normal, whole exome sequencing could
be considered; however, larger cohort studies will be needed
to evaluate diagnostic yield in this setting.
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